Actilyse® is the commercial brand name of Alteplase for Injection, developed by Boehringer Ingelheim. It is a recombinant tissue-type plasminogen activator. It binds to fibrin in thrombi to convert plasminogen into plasmin locally, dissolving occlusive thrombi without inducing systemic extensive…
REMODULIN® is the commercial brand name of Treprostinil Injection, developed by United Therapeutics Corporation. It is a stable prostacyclin analogue delivered via subcutaneous or intravenous infusion. It binds to prostacyclin receptors on vascular smooth muscle and platelets to dilate pulmonary…
HIBOR® is the commercial brand name of Bemiparin Sodium Injection, developed and manufactured by Laboratorios Farmacéuticos ROVI, S.A. It belongs to low molecular weight heparin. It exerts anti-Xa and weak anti-IIa effects to suppress platelet aggregation and coagulation factor activity,…
REPLAGAL® is the commercial brand name of Agalsidase Alfa Concentrated Solution for Infusion, developed by Shire Human Genetic Therapies AB and manufactured by Vetter Pharma-Fertigung GmbH & Co.KG, distributed by Takeda. It is a recombinant human alpha-galactosidase enzyme replacement therapy.…
MOUNJARO® is the commercial brand name of Tirzepatide Injection, developed by Eli Lilly and Company. It is a once-weekly dual GLP‑1 and GIP receptor agonist for subcutaneous injection. It activates two intestinal hormone receptors simultaneously to suppress glucagon release, slow…
Invokana® is the commercial brand name of Canagliflozin Tablets, co-developed by Merck and Janssen. It is an oral sodium-glucose cotransporter 2 inhibitor. It inhibits glucose reabsorption in renal tubules to boost glycosuria excretion, lowering blood glucose independent of pancreatic beta…
STEGLATRO® is the commercial brand name of Ertugliflozin Tablets, developed by MSD. It is an oral sodium-glucose cotransporter 2 inhibitor. It blocks glucose reabsorption in renal tubules to promote urinary glucose excretion, lowering blood sugar independent of pancreatic beta cell…
Lyxumia® is the international commercial brand name of Lixisenatide Injection, developed by Sanofi. It is a short-acting once-daily GLP‑1 receptor agonist for subcutaneous injection. It targets postprandial blood glucose by delaying gastric emptying and suppressing meal-stimulated glucagon secretion, delivering glucose-dependent…
Victoza® is the commercial brand name of Liraglutide Injection, developed by Novo Nordisk. It is a once-daily injectable GLP‑1 receptor agonist. It activates GLP‑1 receptors to inhibit glucagon release, delay gastric emptying and reduce appetite, lowering blood glucose in a…
Trulicity® is the commercial brand name of Dulaglutide Injection, developed by Eli Lilly and Company. It is a long-acting GLP‑1 receptor agonist administered once weekly subcutaneously. It activates GLP‑1 receptors to suppress glucagon secretion, slow gastric emptying, reduce food intake…